Biogen Idec and Adimab Expand Collaboration

  Biogen Idec and Adimab Expand Collaboration

      Biogen Idec 2^nd Pharma Partner to Internalize the Adimab Platform

Business Wire

LEBANON, N.H. -- July 26, 2013

Adimab, LLC, a leader in the discovery of fully human monoclonal and
bispecific antibodies, today announced an expanded collaboration with Biogen
Idec for the discovery of antibody based therapeutics.

Under the terms of the agreement, Adimab will license and transfer its
proprietary antibody discovery platform (the “Adimab Platform”) to Biogen Idec
and enable Biogen Idec researchers to utilize the Adimab technology for the
discovery, optimization of all antibody formats, including bispecific
antibodies. Following GSK, Biogen Idec will be the second pharmaceutical
company to internalize the Adimab Platform. Biogen Idec will receive a custom
human antibody library that is unique and exclusive to Biogen Idec and will
obtain a license to the Adimab Platform for use in Biogen Idec’s targeted
therapeutic areas. In addition, Biogen Idec has secured an option to receive
continued improvements to the Adimab Platform, including access to new
antibody libraries. Adimab will receive an undisclosed upfront, signing fee,
plus future payments upon achievement of specified preclinical and clinical
milestones, as well as royalties and additional future payments upon
achievement of specified commercial milestones on therapeutic products.

“We are excited to expand our relationship with Biogen Idec,” said Tillman
Gerngross, Chief Executive Officer of Adimab. “Biogen Idec is one of the more
sophisticated buyers in the industry, and having earned their endorsement
through a competitive evaluation process validates our focus on offering the
premier antibody discovery technology in the industry. The two BD teams worked
hard to find the right structure to allow Biogen Idec to bring the Adimab
technology in house.”

“This collaboration is the type of relationship we have been looking for. Our
goal has always been to become the industry’s best technology provider for all
antibody based therapeutics,” said Guy van Meter, VP of BD at Adimab. “As
therapeutic programs get more complex and challenging, biotech and pharma
companies need access to discovery technologies that can provide a competitive
advantage.”

“The roots of Biogen Idec’s success are based in discovery science, and
antibody biologic drug candidates are an important part of that,” said Werner
Meier, Vice President of Biologics Drug Discovery at Biogen Idec. “In order to
identify the best antibody discovery technology to support these efforts, we
engaged in a rigorous selection process and Adimab was the clear winner. We
believe Adimab’s platform will help us to accelerate our drug discovery
efforts as we search for the next generation of antibodies to treat
neurodegenerative and autoimmune diseases.”

Over the past four years, Adimab has established collaborations with multiple
leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly,
Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK.
Adimab’s collaborations range from single target funded discovery projects, to
larger multi-target funded discovery collaborations, as well as full license,
transfer and enablement of the Adimab Platform to pharma companies. These
collaborations focus on IgG discovery, optimization, humanization and/or
bispecifics for therapeutic products.

About Adimab
Adimab’s integrated antibody discovery and optimization platform provides
unprecedented speed from antigen to purified, full-length human IgGs. Adimab
offers fundamental advantages by delivering diverse panels of therapeutically
relevant antibodies that meet the most aggressive standards for affinity,
epitope coverage, species cross-reactivity and developability. Adimab enables
its partners to rapidly expand their biologics pipelines through a broad
spectrum of technology access arrangements. For more information, visit
http://www.adimab.com.

Contact:

Adimab, LLC.
Guy Van Meter, 603-653-5775
VP of Business Development